Pulmonary Therapy

, Volume 5, Issue 2, pp 213–220 | Cite as

Dehydroepiandrosterone Supplementation May Benefit Women with Asthma Who Have Low Androgen Levels: A Pilot Study

  • Nadzeya Marozkina
  • Joe Zein
  • Mark D. DeBoer
  • Laurie Logan
  • Laura Veri
  • Kristie Ross
  • Benjamin GastonEmail author
Open Access
Original Research



Among individuals with severe asthma, FEV1 is low in individuals with low dehydroepiandrosterone (DHEA) sulfate (DHEAS) levels. In the Severe Asthma Research Program (SARP), no women with DHEAS > 200 μg/dL had an FEV1 < 60% predicted. DHEA has benefited patients with COPD and pulmonary hypertension in small trials. Therefore, we hypothesized that DHEA supplementation may improve FEV1 in asthmatic women with low DHEAS.


Premenopausal, nonsmoking, otherwise healthy women, 18-50 years old, with mild or moderate asthma and baseline FEV1 > 60% predicted received 100 mg DHEA orally every 12 h for 2 weeks. Spirometry and DHEAS were measured at the initial visit and 2 weeks later, after completion of DHEA treatment. Based on our previous work, the primary outcome variable for this pilot study was post-albuterol spirometry in the low-DHEAS group. Subjects also continued their other routine asthma management.


Serum DHEAS increased with DHEA treatment in women with starting DHEAS < 200 µg/dL: this increase was from 71 ± 23 to 725 ± 295 µg/dL (n = 10; p = 0.0001). The increase in the high-DHEAS group was smaller. Post-albuterol FEV1 increased by 51 mL, from 3.026 ± 0.5 to 3.077 ± 0.49 L (n = 10; p = 0.034 by paired t test, significant after Bonferroni), in women with low DHEAS. In the high-DHEAS group (baseline DHEAS ≥ 200 µg/dl), post-albuterol FEV1 did not change significantly (n = 3, p = NS). Three subjects were excluded: one had comorbid COPD, one could not perform spirometry, and one did not take the DHEA. There were no adverse effects of DHEA treatment in this trial.


Endocrine treatments (corticosteroids) are a mainstay of anti-inflammatory management for moderate and severe asthma. Their use has improved asthma outcomes. Androgens also reduce airway inflammation and promote airway smooth muscle relaxation, but are rarely used clinically for asthma treatment. Our results suggest that the over-the-counter steroid DHEA may improve lung function in asthma outcomes among women with DHEAS < 200 ug/dL.


Asthma Dehydroepiandrosterone (DHEA) Lung function 

Key Summary Points

Endocrine treatments (corticosteroids) are a mainstay of anti-inflammatory management for moderate and severe asthma.

Their use has improved asthma outcomes.

Androgens also reduce airway inflammation and promote airway smooth muscle relaxation, but are rarely used clinically.

Our results suggest that the over-the-counter steroid DHEA may also improve lung function in asthma outcomes among women with DHEAS < 200 ug/dL.


Background and Significance Regarding Androgens for Patients with Asthma Who Have Low Circulating Androgen Levels

In the United States, asthma affects over 8% of the population, leading to annual healthcare expenditures in excess of $20 billion [1, 2, 3, 4, 5]. In severe asthma, chronic symptoms and exacerbation-prone disease persist despite the use of corticosteroids and other interventions in established management protocols [6, 7, 8, 9]. Severe asthma accounts for the majority of the morbidity, mortality, and healthcare expenditures associated with asthma [7, 8, 9]. In the Severe Asthma Research Program (SARP), we investigated the distinct pathophysiological features of asthma in general, and severe asthma in particular [6, 7, 9, 10, 11, 12, 13]. In the SARP, we used the asthma and severe asthma definitions in the American Thoracic Society/European Respiratory Society consensus guidelines [9].

Asthma prevalence increases with age in women relative to men [3, 12]. A particular focus of our SARP investigation has been to understand the relationship between asthma severity and sex hormones. Before puberty, the majority of patients with asthma are boys, while the majority of late adolescents and adults with asthma are women [12, 13, 14]. We measured circulating sex steroid levels and sex hormone-binding globulin (SHBG) in SARP subjects; specific hormones measured were estradiol, testosterone, progesterone, and dehydroepiandrosterone sulfate (DHEAS) [15]. Note that DHEAS is endogenously sulfated DHEA, and accounts for the majority of circulating DHEA. DHEA is synthesized from cholesterol via the enzymes cholesterol side-chain cleavage enzyme (CYP11A1; P450scc) and 17α-hydroxylase/17,20-lyase (CYP17A1), with pregnenolone and 17α-hydroxypregnenolone as intermediates [16]. It functions as a metabolic intermediate in the biosynthesis of the androgen and estrogen sex steroids both in the gonads and in various other tissues. Metabolites of DHEA include DHEA-S, 7α-hydroxy-DHEA, 7β-hydroxy-DHEA, 7-keto-DHEA, 7α-hydroxyepiandrosterone, and 7β-hydroxyepiandrosterone, as well as androstenediol and androstenedione [17].

We found that post-albuterol FEV1 was strongly associated with low DHEA levels [15] and that DHEAS levels were twice as high in non-severe as in severe asthma. We also found that women with severe asthma had low levels of DHEAS compared with women with non-severe asthma (58.1 vs 131.5 μg/dL, p < 0.001). Strikingly, no women in our initial (SARP 1 and 2) cohort with DHEAS > 200 μg/dL had a forced expiratory volume at 1 s (FEV1, the standard marker for asthmatic airflow obstruction) < 60% predicted. To our knowledge, no other marker in humans is associated with such complete protection from low lung function. These data led us to hypothesize that DHEA supplementation in asthma subjects with low DHEA levels could improve lung function.

Of note, asthmatic men with low total testosterone levels had lower lung function than asthmatic men with normal testosterone levels—consistent with studies in non-asthmatic populations [18, 19]—and total testosterone values in men with severe asthma were lower than those in men with non-severe asthma. These data also suggest a protective effect of androgens on lung function. Further, DHEAS levels were strongly associated with lung function in male children [15]. For the majority of women and younger boys, adrenal-derived DHEAS is the predominant androgen: the effect of testosterone is smaller. Taken together, these data suggest that androgens might improve lung function in asthma patients with low androgen levels. We have focused on DHEAS in women because DHEA supplementation is relatively safe and simple—it is an over-the-counter nutritional supplement used for inflammatory conditions [20, 21, 22, 23, 24, 25, 26, 27, 28, 29]—while testosterone administration involves injection of a controlled substance. Note also that glucocorticoid therapy can suppress endogenous DHEA production [30, 31]. Glucocorticoids are, as a class, steroid hormone derivatives that are beneficial preventively and therapeutically in both chronic and acute asthmatic airway inflammation [8, 9]. Patients with severe asthma tend to be glucocorticoid-refractory, even when treated with high doses [9, 10, 32]. It can be appropriately argued that low lung function associated with low DHEAS levels in our SARP data and related studies [30, 31] may reflect higher corticosteroid dosing used for these refractory patients with low lung function: that is, that low DHEAS might not be causally related to low lung function.

To begin to address whether low lung function is a cause or effect, we performed a pilot study, supplementing low DHEAS women with DHEA to determine whether increasing DHEAS levels by supplementation increased post-albuterol FEV1.

DHEA has benefited patients with COPD [28, 33] and pulmonary hypertension [28, 34] in small trials, as well as animal models [35, 36]. Therefore, we hypothesize that DHEA treatment may also improve asthma outcomes.


Subjects and Approval

We recruited premenopausal, nonsmoking, otherwise healthy women 18–50 years of age with non-severe asthma and a baseline FEV1 > 60% predicted. They were recruited by public advertisement and from pulmonary clinics in Cleveland. All subjects who made inquiry regarding the study were screened and, if they met the criteria, were enrolled, with one exception: one woman declined to participate for family reasons. Inclusion and exclusion criteria were identical to those in the SARP for non-severe asthma, as we have published [37], except as noted in Table 1. Because of the slow turnaround in DHEAS levels, we treated all eligible women, but our target was women with low baseline DHEAS levels. Once we had the initial DHEAS levels, we stratified by level, above and below 200 ug/dL. The study met ethics compliance and received institutional review board approval on 1 November 2016, UHCMC IRB number: 09-16-30. It was not entered into because the protocol was approved and initiated in 2016, before the National Institutes of Health (NIH) clinical trials policy was posted or went into effect (18 January 2017), and it was not an NIH-funded clinical trial.
Table 1

Inclusion and exclusion criteria



Female, 18–50 years old


Asthma, stable and managed by an asthma specialist [9]

Using hormonal contraception, pregnant


Exclusion criteria for SARP [37], including both major comorbidities and smoking


Endocrinopathy such as diabetes or PCOS (polycystic ovarian syndrom) 


Using androgens for any reason


Active asthma exacerbation

FEV1 < 60%


At 8:00 a.m., after withholding medication for 12 h, women underwent a urine pregnancy test as well as a history and physical exam. Those who were not pregnant and were not experiencing asthma exacerbation proceeded with the study. Baseline spirometry, maximum bronchodilator testing, and phlebotomy were performed at the initial visit and 2 weeks later, after the completion of DHEA treatment, according to SARP protocols [7, 37]. Three milliliters of blood were drawn and sent to measure baseline DHEAS and other sex steroid levels (all assays required a total of 400 μL serum in the SARP). All serum was bar-coded in Dr. Marozkina’s lab and stored at −80 °C until assayed.

Subjects received 100 mg DHEA orally every 12 h for 2 weeks, and they also continued their routine asthma management. Patients were given 28 pills by the research pharmacist. Those with non-allergic comorbidities were excluded [7, 8]. The primary outcome variable was post-albuterol FEV1; the secondary outcome variables were circulating DHEAS levels and pre-albuterol spirometry values.

DHEA Preparation

DHEA 100 mg capsules were obtained from General Nutrition Corporation (GNC; Pittsburgh, PA 15222) and distributed by the research pharmacy.

Statistical Analysis

The primary outcome variable was change in post-bronchodilator FEV1. We used the paired Student t test, Bonferroni test, and one-way analysis of variance (ANOVA) on ranks to analyze the data.


In this pilot study, 16 premenopausal women, 18–50 years of age, with non-severe asthma were studied. Three women were excluded from study: one who could not perform reproducible spirometry, one who had COPD, and one non-compliant (no changes in pre-post DHEAS levels). Those with low DHEAS (< 200 ug/dL) and baseline FEV1 < 80% predicted (baseline obstruction) who met the inclusion criteria (Table 1) had been identified in the screening visit. These exclusions included smoking and any major comorbidity.

Serum DHEAS increased after DHEA treatment from 71 ± 23 to 725 ± 295 µg/dL (n = 10; p = 0.0001) in the low-DHEAS group (baseline DHEAS < 200 µg/dl). However, in the high-DHEAS group (baseline DHEAS ≥ 200 µg/dl), the increase in serum DHEAS after DHEA treatment did not reach statistical significance, increasing from 214 ± 18 to 458 ± 170 µg/dL (n = 3; p = NS).

We compared the change in post-albuterol FEV1 (primary outcome) and change in DHEAS in women whose starting DHEAS was < 200 µg/dL. Post-albuterol FEV1 increased by 51 mL, from 3.026 ± 0.5 to 3.077 ± 0.49 L (n = 10; p = 0.034 by paired t test, significant after Bonferroni test), in women with low DHEAS (Table 2). However, in the high-DHEAS group (baseline DHEAS ≥ 200 µg/dl), corrective post-albuterol FEV1 did not change significantly (n = 3, p = NS).
Table 2

Spirometry value changes after DHEA treatment


Low-DHEAS group



No treatment

+ DHEA treatment

Baseline FEV1 change

2.952 ± 0.468

2.986 ± 0.505



Post-albuterol FEV1 change

3.026 ± 0.507

3.077 ± 0.489



We analyzed other respiratory parameters obtained by spirometry, such as pre- and post-albuterol changes in forced vital capacity (FVC), FEV/FVC %, FEV 75/25 following DHEA treatment by one-way ANOVA on ranks, and paired Student t test. In all these parameters, changes did not reach statistical significance.

There were no adverse effects of DHEA treatment reported in any of the patients participating in this trial.


In our two SARP study cohorts combined (SARP 1 and 2; and SARP 3), women with a DHEAS level > 200 µg/dL did not have severely compromised FEV1. Indeed, DHEAS was previously shown to be associated with protection against inflammation in general, and asthmatic airway inflammation in particular [15, 19, 20, 21, 28, 29, 38, 39]. However, the heterogeneity of determinants of androgen levels makes it difficult to ascertain both efficacy and mechanism. In this pilot study, our low-DHEAS adult asthmatic women with airflow obstruction received a 2-week course of DHEA, and the primary outcome variable was improvement in FEV1. We may also have a better understanding of the potential protective effects of androgens that could help explain the tendency of asthma prevalence to increase with age in women relative to men. Cortisol-like compounds have been effective agents for the management of many patients with asthma, but other hormones have not been systemically studied. Here, we have studied the use of a safe, easily available, and inexpensive androgen to treat asthma. This study thus has a high potential for return on investment, improving the health of many patients with severe asthma and reducing asthma healthcare costs.

Potential Mechanisms by which Androgens May Benefit Patients with Asthma

The potential protective effects of DHEAS likely involve effects both on airway smooth muscle and on airway inflammation. Indeed, there is evidence to support cross-talk between DHEAS anti-inflammatory effects and airway smooth muscle relaxation [38, 40]. DHEAS inhibits human airway smooth muscle and fibroblast proliferation [39, 41], may benefit airway epithelial-to-mesenchymal transition [42], and is itself a bronchodilator [43]. It also benefits pulmonary vascular smooth muscle tone, and is used as treatment for human pulmonary arterial hypertension [28]. Note that testosterone also promotes airway smooth muscle relaxation [41].

DHEAS also has anti-inflammatory effects in murine (dust mitel) asthma models, decreasing airway interleukin (IL) 4, IL5, and interferon gamma [44, 45], and reducing airway eosinophilia in an ovalbumin model [38]. Note that testosterone was also recently shown to be associated with decreasing type 2 innate lymphoid cell-mediated inflammation in a murine asthma model [46]. DHEAS is also associated with lower systemic IL6 levels, proposed to be involved in its neuroprotective effects in human stroke [29]. DHEA exerts anti-inflammatory effects observed in a variety of non-asthmatic human conditions [20, 21, 22, 23, 47, 48], in many of which it is used as a nutritional supplement therapy.

This pilot study will be the basis for larger double-blind randomized controlled trials. It was shown previously [21] that nebulized DHEA improves asthma symptoms (reflected by Asthma Control Questionnaire) in moderate-to-severe asthma in a randomized, double-blind, placebo-controlled study. This pilot will be used to power a larger study of oral DHEA supplementation in the future larger double-blind randomized controlled trial.


Corticosteroids related to cortisol are a mainstay of anti-inflammatory treatment for moderate and severe asthma. Their use has improved asthma outcomes. However, androgens also reduce airway inflammation and promote airway smooth muscle relaxation. Our preliminary data suggest that the over-the-counter steroid DHEA also improves lung function in asthma outcomes among women with DHEAS < 200 ug/dL. Low-dose over-the-counter androgen supplementation may benefit certain women with asthma, particularly those with low serum DHEAS levels, and is safe in given doses. Additional studies will be worthwhile.




This study was funded by the Children’s Lung Foundation and (U10HL109250 [SARP]). The Rapid Service Fee was funded by the authors.


All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.


Nadzeya Marozkina, Joe Zein, Mark D. DeBoer, Laurie Logan, Laura Veri, Kristie Ross, and Benjamin Gaston have nothing to disclose.

Compliance with Ethics Guidelines

The study met ethics compliance and received institutional review board approval on 1 November 2016, UHCMC IRB number: 09-16-30. It was not entered into because the protocol was approved and initiated in 2016, before the NIH clinical trials policy was posted or went into effect (18 January 2017), and it was not an NIH-funded clinical trial. Informed consent to participate was given by all participants.


  1. 1.
    Centers for Disease Control National Health Interview Survey, 2012. Source: summary Health Statistics for U.S. Adults: National Health Interview Survey. 2012. Accessed 15 Oct 2019.
  2. 2.
    Centers for Disease Control National Health Interview Survey, 2010, Source: National Ambulatory Medical Care Survey. 2010:Summary Tables, table 13.
  3. 3.
    Centers for Disease Control and Prevention, Vital Signs (monthly statistical report). 2011. Accessed 15 Oct 2019.
  4. 4.
    Slejko JF, Ghushchyan VH, Sucher B, Globe DR, Lin SL, Globe G, et al. Asthma control in the United States, 2008-2010: indicators of poor asthma control. J Allergy Clin Immunol. 2014;133(6):1579–87.PubMedGoogle Scholar
  5. 5.
    Morbidity and Mortality Report. National Center for Health Statistics (NCHS), U.S. CDC. 2003.Google Scholar
  6. 6.
    Marozkina NV, Wang XQ, Stsiapura V, Fitzpatrick A, Carraro S, Hawkins GA, et al. Phenotype of asthmatics with increased airway S-nitrosoglutathione reductase activity. Eur Respir J. 2015;45(1):87–97.PubMedGoogle Scholar
  7. 7.
    Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405–13.PubMedPubMedCentralGoogle Scholar
  8. 8.
    National Heart Lung and Blood Institute. Guidelines for the diagnosis and treatment of asthma (EPR3). 2007. Accessed 15 Oct 2019.
  9. 9.
    Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73.PubMedGoogle Scholar
  10. 10.
    Denlinger LC, Phillips BR, Ramratnam S, Ross K, Bhakta NR, Cardet JC, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017;195(3):302–13.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Greenwald R, Fitzpatrick AM, Gaston B, Marozkina NV, Erzurum S, Teague WG. Breath formate is a marker of airway S-nitrosothiol depletion in severe asthma. PLoS One. 2010;5(7):e11919.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Zein JG, Udeh BL, Teague WG, Koroukian SM, Schlitz NK, Bleecker ER, et al. Impact of age and sex on outcomes and hospital cost of acute asthma in the United States, 2011–2012. PLoS One. 2016;11(6):e0157301.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Becklake MR, Kauffmann F. Gender differences in airway behaviour over the human life span. Thorax. 1999;54(12):1119–38.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Zein JG, Erzurum SC. Asthma is different in women. Curr Allergy Asthma Rep. 2015;15(6):28.PubMedPubMedCentralGoogle Scholar
  15. 15.
    DeBoer MD, Phillips BR, Mauger DT, Zein J, Erzurum SC, Fitzpatrick AM, et al. Effects of endogenous sex hormones on lung function and symptom control in adolescents with asthma. BMC Pulm Med. 2018;18(1):58.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Rainey WE, Nakamura Y. Regulation of the adrenal androgen biosynthesis. J Steroid Biochem Mol Biol. 2008;108(3–5):281–6. 2699571. PMID 17945481).CrossRefPubMedGoogle Scholar
  17. 17.
    Mo Q, Lu SF, Simon NG. Dehydroepiandrosterone and its metabolites: differential effects on androgen receptor trafficking and transcriptional activity. J Steroid Biochem Mol Biol. 2006;99(1):50–8. (PMID 16524719).CrossRefPubMedGoogle Scholar
  18. 18.
    Swartz MA, Tschumperlin DJ, Kamm RD, Drazen JM. Mechanical stress is communicated between different cell types to elicit matrix remodeling. Proc Natl Acad Sci USA. 2001;98(11):6180–5.PubMedGoogle Scholar
  19. 19.
    Mohan SS, Knuiman MW, Divitini ML, James AL, Musk AW, Handelsman DJ, et al. Higher serum testosterone and dihydrotestosterone, but not oestradiol, are independently associated with favourable indices of lung function in community-dwelling men. Clin Endocrinol. 2015;83(2):268–76.Google Scholar
  20. 20.
    Traish AM, Kang HP, Saad F, Guay AT. Dehydroepiandrosterone (DHEA)—a precursor steroid or an active hormone in human physiology. J Sex Med. 2011;8(11):2960–82 (quiz 83).PubMedGoogle Scholar
  21. 21.
    Wenzel SE, Robinson CB, Leonard JM, Panettieri RA Jr. Nebulized dehydroepiandrosterone-3-sulfate improves asthma control in the moderate-to-severe asthma results of a 6-week, randomized, double-blind, placebo-controlled study. Allergy Asthma Proc. 2010;31(6):461–71.PubMedGoogle Scholar
  22. 22.
    Taylor MK, Padilla GA, Stanfill KE, Markham AE, Khosravi JY, Ward MD, et al. Effects of dehydroepiandrosterone supplementation during stressful military training: a randomized, controlled, double-blind field study. Stress (Amsterdam, Netherlands). 2012;15(1):85–96.Google Scholar
  23. 23.
    Weiss EP, Villareal DT, Fontana L, Han DH, Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging. 2011;3(5):533–42.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Stanczyk FZ, Slater CC, Ramos DE, Azen C, Cherala G, Hakala C, et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause (New York, NY). 2009;16(2):272–8.Google Scholar
  25. 25.
    Acacio BD, Stanczyk FZ, Mullin P, Saadat P, Jafarian N, Sokol RZ. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. Fertil Steril. 2004;81(3):595–604.PubMedGoogle Scholar
  26. 26.
    Arlt W, Justl HG, Callies F, Reincke M, Hubler D, Oettel M, et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab. 1998;83(6):1928–34.PubMedGoogle Scholar
  27. 27.
    Buster JE, Casson PR, Straughn AB, Dale D, Umstot ES, Chiamori N, et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. Am J Obstet Gynecol. 1992;166(4):1163–8 (discussion 8-70).PubMedGoogle Scholar
  28. 28.
    La Dumas Roque E, Savineau JP, Metivier AC, Billes MA, Kraemer JP, Doutreleau S, et al. Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study. Annales d’endocrinologie. 2012;73(1):20–5.Google Scholar
  29. 29.
    Hollig A, Thiel M, Stoffel-Wagner B, Coburn M, Clusmann H. Neuroprotective properties of dehydroepiandrosterone-sulfate and its relationship to interleukin 6 after aneurysmal subarachnoid hemorrhage: a prospective cohort study. Crit Care (London, England). 2015;19(1):231. (PMID 25993987).Google Scholar
  30. 30.
    Dorsey MJ, Cohen LE, Phipatanakul W, Denufrio D, Schneider LC. Assessment of adrenal suppression in children with asthma treated with inhaled corticosteroids: use of dehydroepiandrosterone sulfate as a screening test. Ann Allergy Asthma Immunol. 2006;97(2):182–6.PubMedGoogle Scholar
  31. 31.
    Reinke SN, Gallart-Ayala H, Gomez C, Checa A, Fauland A, Naz S, et al. Metabolomics analysis identifies different metabotypes of asthma severity. Eur Respir J. 2017;49(3). (PMID 28356371).PubMedGoogle Scholar
  32. 32.
    Phipatanakul W, Mauger DT, Sorkness RL, Gaffin JM, Holguin F, Woodruff PG, et al. Effects of age and disease severity on systemic corticosteroid responses in asthma. Am J Respir Crit Care Med. 2017;195(11):1439–48.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Zurfluh S, Nickler M, Ottiger M, Steuer C, Kutz A, Christ-Crain M, et al. Association of adrenal hormone metabolites and mortality over a 6-year follow-up in COPD patients with acute exacerbation. Clin Chem Lab Med. 2018;56(4):669–80.PubMedGoogle Scholar
  34. 34.
    Dubuis E. DHEA treatment of pulmonary hypertension: new insights into a complex mechanism. Cardiovasc Res. 2007;74(3):337–8.PubMedGoogle Scholar
  35. 35.
    Zhang YT, Xue JJ, Wang Q, Cheng SY, Chen ZC, Li HY, et al. Dehydroepiandrosterone attenuates pulmonary artery and right ventricular remodeling in a rat model of pulmonary hypertension due to left heart failure. Life Sci. 2019;219:82–9.PubMedGoogle Scholar
  36. 36.
    Alzoubi A, Toba M, Abe K, O’Neill KD, Rocic P, Fagan KA, et al. Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2013;304(12):H1708–18.PubMedGoogle Scholar
  37. 37.
    Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore WC, et al. Baseline features of the severe asthma research program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract. 2018;6(2):545.e4–554.e4.Google Scholar
  38. 38.
    Liou CJ, Huang WC. Dehydroepiandrosterone suppresses eosinophil infiltration and airway hyperresponsiveness via modulation of chemokines and Th2 cytokines in ovalbumin-sensitized mice. J Clin Immunol. 2011;31(4):656–65.PubMedGoogle Scholar
  39. 39.
    Mendoza-Milla C, Valero Jimenez A, Rangel C, Lozano A, Morales V, Becerril C, et al. Dehydroepiandrosterone has strong antifibrotic effects and is decreased in idiopathic pulmonary fibrosis. Eur Respir J. 2013;42(5):1309–21.PubMedGoogle Scholar
  40. 40.
    Bosse Y. Endocrine regulation of airway contractility is overlooked. J Endocrinol. 2014;222(2):R61–73.PubMedGoogle Scholar
  41. 41.
    Kouloumenta V, Hatziefthimiou A, Paraskeva E, Gourgoulianis K, Molyvdas PA. Non-genomic effect of testosterone on airway smooth muscle. Br J Pharmacol. 2006;149(8):1083–91.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Xu L, Xiang X, Ji X, Wang W, Luo M, Luo S, et al. Effects and mechanism of dehydroepiandrosterone on epithelial-mesenchymal transition in bronchial epithelial cells. Exp Lung Res. 2014;40(5):211–21.PubMedGoogle Scholar
  43. 43.
    Espinoza J, Montano LM, Perusquia M. Nongenomic bronchodilating action elicited by dehydroepiandrosterone (DHEA) in a guinea pig asthma model. J Steroid Biochem Mol Biol. 2013;138:174–82.PubMedGoogle Scholar
  44. 44.
    Yu CK, Liu YH, Chen CL. Dehydroepiandrosterone attenuates allergic airway inflammation in Dermatophagoides farinae-sensitized mice. J Microbiol Immunol Infect. 2002;35(3):199–202.PubMedGoogle Scholar
  45. 45.
    Yu CK, Yang BC, Lei HY, Chen YC, Liu YH, Chen CC, et al. Attenuation of house dust mite Dermatophagoides farinae-induced airway allergic responses in mice by dehydroepiandrosterone is correlated with down-regulation of TH2 response. Clin Exp Allergy. 1999;29(3):414–22.PubMedGoogle Scholar
  46. 46.
    Cephus JY, Stier MT, Fuseini H, Yung JA, Toki S, Bloodworth MH, et al. Testosterone attenuates group 2 innate lymphoid cell-mediated airway inflammation. Cell Rep. 2017;21(9):2487–99.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology. 2003;144(8):3449–55.PubMedGoogle Scholar
  48. 48.
    Hampl V, Bibova J, Povysilova V, Herget J. Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats. Eur Respir J. 2003;21(5):862–5.PubMedGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (, which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Nadzeya Marozkina
    • 1
  • Joe Zein
    • 1
  • Mark D. DeBoer
    • 2
  • Laurie Logan
    • 3
  • Laura Veri
    • 3
  • Kristie Ross
    • 1
    • 3
  • Benjamin Gaston
    • 1
    • 3
    Email author
  1. 1.Case Western Reserve UniversityClevelandUSA
  2. 2.University of VirginiaCharlottesvilleUSA
  3. 3.Rainbow Babies and Children’s HospitalClevelandUSA

Personalised recommendations